Qiagen N.V. $QGEN Shares Bought by Graham Capital Management L.P.

Graham Capital Management L.P. boosted its holdings in Qiagen N.V. (NYSE:QGEN) by 92.7% in the 1st quarter, HoldingsChannel.com reports. The firm owned 68,114 shares of the company’s stock after buying an additional 32,774 shares during the quarter. Graham Capital Management L.P.’s holdings in Qiagen were worth $2,735,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in QGEN. SVB Wealth LLC acquired a new position in Qiagen in the first quarter valued at $31,000. ANTIPODES PARTNERS Ltd acquired a new position in Qiagen in the first quarter valued at $94,000. Tower Research Capital LLC TRC increased its stake in Qiagen by 770.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 2,490 shares of the company’s stock valued at $111,000 after purchasing an additional 2,204 shares during the last quarter. GAMMA Investing LLC increased its stake in Qiagen by 93.9% in the first quarter. GAMMA Investing LLC now owns 2,943 shares of the company’s stock valued at $118,000 after purchasing an additional 1,425 shares during the last quarter. Finally, Federated Hermes Inc. acquired a new position in Qiagen in the first quarter valued at $150,000. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Qiagen Stock Performance

Shares of NYSE:QGEN opened at $46.53 on Monday. The firm has a market capitalization of $10.34 billion, a PE ratio of 27.49, a P/E/G ratio of 2.57 and a beta of 0.64. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.61 and a quick ratio of 1.35. The business has a 50-day moving average of $48.71 and a two-hundred day moving average of $44.16. Qiagen N.V. has a 12 month low of $37.63 and a 12 month high of $51.88.

Qiagen (NYSE:QGEN) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $0.60 EPS for the quarter, hitting the consensus estimate of $0.60. The company had revenue of $533.54 million during the quarter, compared to analyst estimates of $523.97 million. Qiagen had a return on equity of 14.77% and a net margin of 18.30%.The firm’s revenue was up 7.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.55 earnings per share. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. As a group, research analysts forecast that Qiagen N.V. will post 2.26 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. UBS Group upped their target price on Qiagen from $48.00 to $50.00 and gave the company a “neutral” rating in a research note on Thursday, August 7th. Cowen reiterated a “hold” rating on shares of Qiagen in a research note on Thursday, August 7th. Bank of America upped their target price on Qiagen from $50.00 to $53.00 and gave the company a “buy” rating in a research note on Thursday, June 26th. Barclays assumed coverage on Qiagen in a research note on Tuesday, June 24th. They issued an “overweight” rating and a $55.00 target price for the company. Finally, Wall Street Zen lowered Qiagen from a “strong-buy” rating to a “buy” rating in a research note on Monday, August 11th. Three equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $49.69.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.